Edition:
India

Nicox SA (NCOX.PA)

NCOX.PA on Paris Stock Exchange

9.10EUR
21 Feb 2018
Change (% chg)

€-0.01 (-0.11%)
Prev Close
€9.11
Open
€9.11
Day's High
€9.13
Day's Low
€9.03
Volume
51,108
Avg. Vol
209,726
52-wk High
€13.68
52-wk Low
€7.65

Chart for

About

Nicox SA is a France-based international ophthalmic company. It is engaged in the field of the research, development and future commercialization of investigational drugs for ophthalmological diseases. The Company’s aim is to build a portfolio of therapeutic products addressing the needs of eye care practitioners and patients.... (more)

Overall

Beta: 0.53
Market Cap(Mil.): €275.62
Shares Outstanding(Mil.): 29.17
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.60
EPS (TTM): -- -- --
ROI: -- 14.90 10.66
ROE: -- 16.41 14.30

BRIEF-Nicox Updates on Drug Development And Outlines 2018 Activities

* RESOURCES IN 2018 WILL BE FOCUSED ON ADVANCING NICOX'S PIPELINE CANDIDATES NCX 470 AND NCX 4251 TOWARDS MID-STAGE CLINICAL DEVELOPMENT

19 Dec 2017

BRIEF-Bausch + Lomb and Nicox announces FDA approval of Vyzulta

* Bausch + Lomb and Nicox announce FDA approval of Vyzulta™ (latanoprostene Bunod Ophthalmic Solution), 0.024%

03 Nov 2017

BRIEF-‍Nicox enters research collaboration with Re-Vana Therapeutics

* ‍Nicox enters research collaboration with Re-Vana Therapeutics on its next generation of stand-alone no-donors in a novel sustained release ophthalmic formulation​

20 Oct 2017

BRIEF-Nicox and pSivida enter strategic collaboration agreement

* REG-NICOX AND PSIVIDA ENTER STRATEGIC COLLABORATION AGREEMENT TO DEVELOP SUSTAINED RELEASE DRUG TO LOWER INTRAOCULAR PRESSURE IN PATIENTS WITH GLAUCOMA

10 Oct 2017

BRIEF-Nicox and pSivida enter collaboration agreement to develop sustained release drug for glaucoma patients​

* Nicox-Co and pSivida enter strategic collaboration agreement to develop sustained release drug to lower intraocular pressure in patients with glaucoma​

10 Oct 2017

BRIEF-Nicox announces licensing agreement with Eyevance

* ANNOUNCES LICENSING AGREEMENT WITH EYEVANCE FOR COMMERCIALIZATION OF ZERVIATETM IN UNITED STATES

21 Sep 2017

BRIEF-Nicox H1 operating loss narrows to ‍​11.6 million euros

* ‍ZERVIATE (CETIRIZINE OPHTHALMIC SOLUTION), 0.24% NEW DRUG APPLICATION (NDA) APPROVED​

08 Sep 2017

Earnings vs. Estimates